Expression of CD40 and CD40L on tumor cells: The role of their interaction and new approach to immunotherapy

Experimental Oncology

Volumn 29, Issue 1, 2007, Pages 2-12

  Bereznaya, N M ^a   Chekhun, V F ^a  

^a R E KAVETSKY INSTITUTE OF EXPERIMENTAL PATHOLOGY   (Ukraine)

Author keywords

CD40; CD40 CD40L interaction; CD40L; Immunotherapy; Tumor

Indexed keywords

ADENOVIRUS VECTOR; CANCER VACCINE; CARBOPLATIN; CD40 ANTIGEN; CD40 LIGAND; LENALIDOMIDE;

APOPTOSIS; CANCER CELL; CANCER GROWTH; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFECT; GROWTH INHIBITION; HUMAN; LYMPHOMA; MACROPHAGE; MONOCYTE; MYELOMA; NATURAL KILLER CELL; NONHUMAN; PROTEIN EXPRESSION; PROTEIN INTERACTION; REVIEW; TUMOR IMMUNITY;

ANIMALS; ANTIGENS, CD40; CD40 LIGAND; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 34248153303     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Paulie S, Rosen A, Ehlin-Henriksson B, Braesch-Andersen S, Jakobson E, Koho H, Perlmann P. The human B lymphocyte and carcinoma antigen, CDw40, is a phosphoprotein involved in growth signal transduction. J Immunol 1989; 142: 590-5.
2. Ledbetter JA, Shu G, Gallagher M, Clark EA. Augmentation of normal and malignant B-cell proliferation by monoclonal antibody to the B-cell-specific antigen BP50 (CDW40). J Immunol 1987; 138: 788-94.
3. Nowak AK, Robinson BW, Lake RA. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res 2003; 63: 4490-6.
4. Pirozzi G, Lombari V, Zanzi D, Ionna F, Lombardi ML, Errico S, Ruggiero G, Manzo C. CD40 expressed on human melanoma cells mediates T-cell co-stimulation and tumor cell growth. Int Immunol 2000; 12: 787-95.
5. Ottaiano A, Pisano C, De Chiara A, Ascierto PA, Botti G, Barletta E, Apice G, Gridelli C, Iaffaioli VR. CD40 activation as potential tool in malignant neoplasms. Tumori 2002; 88: 361-6.
6. Villarroel Dorrego M, Whawell SA, Speight PM, Barrett AW. Transfection and ligation of CD40 in human oral keratinocytes affect proliferation, adhesion and migration but not apoptosis in vitro. Clin Exp Dermatol 2006; 31: 266-71.
7. Pinzon-Charry A, Schmidt CW, Lopez JA. The key role of CD40 ligand in overcoming tumor-induced dendritic cell dysfunction. Breast Cancer Res 2006; 8: 402.
8. Noelle RJ, Erickson LD. Determinations of B cell fate in immunity and autoimmunity. Curr Dis Autoimmun 2005; 8: 1-24.
9. Koppold B, Sauer G, Buening H, Hallek M, Kreienberg R, Deissler H, Kurzeder C. Chemotherapeutic agents enhance AAV2-mediated gene transfer into breast cancer cells promoting CD40 ligand-based immunotherapy. J Cancer Res Clin Oncol 2006; 132: 787-94.
10. Von Leoprechting A, van der Bruggen P, Pahl HL, Aruffo A, Simon JC. Stimulation of CD40 on immunogenic human malignant melanomas augments their cytotoxic T lymphocyte-mediated lysis and induces apoptosis. Cancer Res 1999; 59: 1287-94.
11. Wingett DG, Vestal RE, Forcier K, Hadjokas N, Nielson CP. CD40 is functionally expressed on human breast carcinomas: variable inducibility by cytokines and enhancement of Fas-mediated apoptosis. Breast Cancer Res Treat 1998; 50: 27-36.
12. Hirano A, Longo DL, Taub DD, Ferris DK, Young LS, Eliopoulos AG, Agathanggelou A, Cullen N, Macartney J, Fanslow WC, Murphy WJ. Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand. Blood 1999; 93: 2999-3007.
13. Posner MR, Cavacini LA, Upton MP, Tillman KC, Gornstein ER, Norris CM Jr. Surface membrane-expressed CD40 is present on tumor cells from squamous cell cancer of the head and neck in vitro and in vivo and regulates cell growth in tumor cell lines. Clin Cancer Res 1999; 5: 2261-70.
14. Thomas WD, Smith MJ, Si Z, Hersey P. Expression of the co-stimulatory molecule CD40 on melanoma cells. Int J Cancer 1996; 68: 795-801.
15. Van den Oord JJ, Maes A, Stas M, Nuyts J, Battocchio S, Kasran A, Garmyn M, De Wever I, De Wolf-Peeters C. CD40 is a prognostic marker in primary cutaneous malignant melanoma. Amer J Pathol 1996; 149: 1953-61.
16. Tan J, Town T, Mori T, Obregon D, Wu Y, DelleDonne A, Rojiani A, Crawford F, Flavell RA, Mullan M. CD40 is expressed and functional on neuronal cells. EMBO J 2002; 21: 643-52.
17. Airoldi I, Lualdi S, Bruno S, Raffaghello L, Occhino M, Gambini C, Pistoia V, Corrias MV. Expression of costimulatory molecules in human neuroblastoma. Evidence that CD40+ neuroblastoma cells undergo apoptosis following interaction with CD40L. Brit J Cancer 2003; 88: 1527-36.
18. Gao YL, Shi HZ, Liu M, Gu XS. Inhibition of human glioma cell growth by a soluble recombinant human CD40 ligand. Ai Zheng 2002; 21: 1112-5.
19. Tong AW, Papayoti MH, Netto G, Armstrong DT, Ordonez G, Lawson JM, Stone MJ. Growth-inhibitory effects of CD40 ligand (CD154) and its endogenous expression in human breast cancer. Clin Cancer Res 2001; 1: 691-703.
20. Fan P, Wang S, Liu X, Zhen L, Wu Z. Major histocompatibility complex class II antigen and costimulatory molecule expression on the surface of breast cancer cells. Zhonghua Zhong Liu Za Zhi 2002; 24: 327-30.
21. Pericle F, Epling-Burnette PK, Podack ER, Wei S, Djeu JY. CD40-CD40L interactions provide "third-party" costimulation for T-cell response against B7-1-transfected human breast tumor cells. J Leukoc Biol 1997; 61: 201-8.
22. Hakkarainen T, Hemminki A, Pereboev AV, Barker SD, Asiedu CK, Strong TV, Kanerva A, Wahlfors J, Curiel DT. CD40 is expressed on ovarian cancer cells and can be utilized for targeting adenoviruses. Clin Cancer Res 2003; 9: 619-24.
23. Holub M, Zakeri SM, Lichtenberger C, Pammer J, Paolini P, Leifeld L, Rockenschaub S, Wolschek MF, Steger G, Willheim M, Gangl A, Reinisch W. Heterogeneous expression and regulation of CD40 in human hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2003; 15: 119-26.
24. Marshall AJ, Niiro H, Lerner CG, Yun TJ, Thomas S, Disteche CM, Clark EA. A novel B lymphocyte-associated adaptor protein, Bam32, regulates antigen receptor signaling downstream of phosphatidylinositol 3-kinase. J Exp Med 2000; 191: 1319-32.
25. Greten TF, Ott M. CD40 in hepatocellular carcinoma: relevant or not? Eur J Gastroenterol Hepatol 2003; 15: 113-4.
26. Berezhnaya NM, Chekhun VF. Immunology of tumor growth. Kiev: Naukova Dumka, 2005: 792 p (In Russian).
27. Ouaaz F, Arron J, Zheng Y, Choi Y, Beg AA. Dendritic cell development and survival require distinct NF-kappaB subunits. Immunity 2002; 16: 257-70.
28. Buhtoiarov IN, Lum H, Berke G, Paulnock DM, Sondel PM, Rakhmilevich AL. CD40 ligation activates murine macrophages via an IFN-gamma-dependent mechanism resulting in tumor cell destruction in vitro. J Immunol 2005; 174: 6013-22.
29. Buhtoiarov IN, Lum HD, Berke G, Sondel PM, Rakhmilevich AL. Synergistic activation of macrophages via CD40 and TLR9 results in T cell independent antitumor effects. J Immunol 2006; 176: 309-18.
30. Hill SC, Youde SJ, Man S, Teale GR, Baxendale AJ, Hislop A, Davies CC, Luesley DM, Blom AM, Rickinson AB, Young LS, Eliopoulos AG. Activation of Cl carcinoma cells facilitates CTL responses and augments chemotherapy-induced apoptosis. J Immunol 2005; 174: 41-50.
31. von Bergwelt-Baildon M, Maecker B, Schultze J, Gribben JG. CD40 activation: potential for specific immunotherapy in B-CLL. Ann Oncol 2004; 15: 853-7.
32. Ritchie DS, Yang J, Hermans IF, Ronchese F. B-Lymphocytes activated by CD40 ligand induce an antigen-specific anti-tumour immune response by direct and indirect activation of CD8(+) T-cells. Scand J Immunol 2004; 60: 543-51.
33. Liu Y, Xia D, Li F, Zheng C, Xiang J. Intratumoral administration of immature dendritic cells following the adenovirus vector encoding CD40 ligand elicits significant regression of established myeloma. Cancer Gene Ther 2005: 12: 122-32.
34. Alexandroff AB, Jackson AM, Paterson T, Haley JL, Ross JA, Longo DL, Murphy WJ, James K, Taub DD. Role for CD40-CD40 ligand interactions in the immune response to solid tumours. Mol Immunol 2000; 37: 515-26.
35. Feder-Mengus C, Schultz-Thater E, Oertli D, Marti WR, Heberer M, Spagnoli GC, Zajac P. Nonreplicating recombinant vaccinia virus expressing CD40 ligand enhances APC capacity to stimulate specific CD4+ and CD8+ T cell responses. Hum Gene Ther 2005; 16: 348-60.
36. Tai YT, Li XF, Catley L, Coffey R, Breitkreutz I, Bae J, Song W, Podar K, Hideshima T, Chauhan D, Schlossman R, Richardson P, Treon SP, Grewal IS, Munshi NC, Anderson KC. Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. Cancer Res 2005; 65: 11712-20.
37. Bergamo A, Bataille R, Pellat-Deceunynck C. CD40 and CD95 induce programmed cell death in the human myeloma cell line XG2. Br J Haematol 1997; 97: 652-5.
38. Ciaravino G, Bhat M, Manbeian CA, Teng NN. Differential expression of CD40 and CD95 in ovarian carcinoma. Eur J Gynaecol Oncol 2004; 25: 27-32.
39. Georgopoulos NT, Steele LP, Thomson MJ, Selby PJ, Southgate J, Trejdosiewicz LK. A novel mechanism of CD40-induced apoptosis of carcinoma cells involving TRAF3 and JNK/AP-1 activation. Cell Death Differ 2006; 13: 1789-801.
40. Gibson S, Shillitoe EJ. Analysis of apoptosis-associated genes and pathways in oral cancer cells. J Oral Pathol Med 2006; 35: 146-54.
41. Chen H, Li M, Campbell RA, Burkhardt K, Zhu D, Li SG, Lee HJ, Wang C, Zeng Z, Gordon MS, Bonavida B, Berenson JR. Interference with nuclear factor kappa B and c-Jun NH2-terminal kinase signaling by TRAF6C small interfering RNA inhibits myeloma cell proliferation and enhances apoptosis. Oncogene 2006; 25: 6520-7.
42. Bugajska U, Georgopoulos NT, Southgate J, Johnson PW, Graber P, Gordon J, Selby PJ, Trejdosiewicz LK. The effects of malignant transformation on susceptibility of human urothelial cells to CD40-mediated apoptosis. J Natl Cancer Inst 2002; 94: 1381-95.
43. Prigione I, Corrias MV, Airoldi I, Raffaghello L, Morandi F, Bocca P, Cocco C, Ferrone S, Pistoia V. Immunogenicity of human neuroblastoma. Ann N Y Acad Sci 2004; 1028: 69-80.
44. Cao W, Cavacini LA, Tillman KC, Posner MR. CD40 function in squamous cell cancer of the head and neck. Oral Oncol 2005; 41: 462-9.
45. Davies CC, Bem D, Young LS, Eliopoulos AG. NF-kappaB overrides the apoptotic program of TNF receptor 1 but not CD40 in carcinoma cells. Cell Signal 2005; 17: 729-38.
46. de Totero D, Meazza R, Zupo S, Cutrona G, Matis S, Colombo M, Balleari E, Pierri I, Fabbi M, Capaia M, Azzarone B, Gobbi M, Ferrarini M, Ferrini S. Interleukin-21 receptor (IL-21R) is up-regulated by CD40 triggering and mediates proapoptotic signals in chronic lymphocytic leukemia B cells. Blood 2006; 107: 3708-15.
47. Teoh G, Tai YT, Urashima M., Shirahama S, Matsuzaki M, Chauhan D, Treon SP, Raje N, Hideshima T, Shima Y, Anderson KC. CD40 activation mediates p53-dependent cell cycle regulation in human multiple myeloma cell lines. Blood 2000; 95: 1039-46.
48. Urashima M, Chauhan D, Uchiyama H, Freeman GJ, Anderson KC. CD40 ligand triggered interleukin-6 secretion in multiple myeloma. Blood 1995; 85: 1903-12.
49. Berezhnaya NM, Chekhun VF. The system of interleukins and cancer. Kiev: DIA, 2000; 224 p (In Russian).
50. Teoh G, Urashima M, Greenfield EA, Nguyen KA, Lee JF, Chauhan D, Ogata A, Treon SP, Anderson KC. The 86-kD subunit of Ku autoantigen mediates homotypic and heterotypic adhesion of multiple myeloma cells. J Clin Invest 1998; 101: 1379-88.
51. Voorzanger-Rousselot N, Blay JY. Coexpression of CD40 and CD40L on B lymphoma and carcinoma cells: an autocrine anti-apoptotic role. Leuk Lymphoma 2004; 45: 1239-45.
52. Voorzanger-Rousselot N, Alberti L, Blay JY. CD40L induces multidrug resistance to apoptosis in breast carcinoma and lymphoma cells through caspase independent and dependent pathways. BMC Cancer 2006; 18: 75.
53. Yamaguchi H, Tanaka F, Sadanaga N, Ohta M, Inoue H, Mori M. Stimulation of CD40 inhibits Fas- or chemotherapy-mediated apoptosis and increases cell motility in human gastric carcinoma cells. Int J Oncol 2003; 23: 1697-702.
54. Jakobson E, Jonsson G, Bjorck P, Paulie S. Stimulation of CD40 in human bladder carcinoma cells inhibits anti-Fas/APO-1 (CD95)-induced apoptosis. Int J Cancer 1998; 77: 849-53.
55. Wang TL, Huang JA, Yu GH, Mao YX, Wang GJ, Zhang XG. Biological effects of soluble CD40 ligand on lung cancer cell line A549 and its mechanism. Ai Zheng 2004; 23: 1278-82.
56. Biancone L, Cantaluppi V, Boccellino M, Del Sorbo L, Russo S, Albini A, Stamenkovic I, Camussi G. Activation of CD40 favors the growth and vascularization of Kaposi's sarcoma. J Immunol 1999; 163: 6201-8.
57. Ray DM, Akbiyik F, Bernstein SH, Phipps RP. CD40 engagement prevents peroxisome proliferator-activated receptor gamma agonist-induced apoptosis of B lymphocytes and B lymphoma cells by an NF-kappaB-dependent mechanism. J Immunol 2005; 174: 4060-9.
58. Walker SR, Redlinger RE Jr, Barksdale EM Jr. Neuroblastoma-induced inhibition of dendritic cell IL-12 production via abrogation of CD40 expression. J Pediatr Surg 2005; 40: 244-9.
59. Todryk SM, Tutt AL, Green MH, Smallwood JA, Halanek N, Dalgleish AG, Glennie MJ. CD40 ligation for immunotherapy of solid tumours. J Immunol Methods 2001; 248: 139-47.
60. Kim SW, Lee HS, Yoon SK, Chung WC, Cho YS, Jeong JJ, Lee IS, Lee KM, Lee DS, Choi MG, Chung IS, Park DH. Expression of CD40 in gastric cancer and its effect on the apoptosis of gastric cancer cells. Korean J Gastroenterol 2003; 42: 274-82.
61. Dzojic H, Loskog A, Totterman TH, Essand M. Adenovirus-mediated CD40 ligand therapy induces tumor cell apoptosis and systemic immunity in the TRAMP-C2 mouse prostate cancer model. Prostate 2006; 66: 831-8.
62. Nakajima A, Kodama T, Morimoto S, Azuma M, Takeda K, Oshima H, Yoshino S, Yagita H, Okumura K. Antitumor effect of CD40 ligand: elicitation of local and systemic antitumor responses by IL-12 and B7. J Immunol 1998; 161: 1901-7.
63. Grossmann ME, Brown MP, Brenner MK. Antitumor responses induced by transgenic expression of CD40 ligand. Hum Gene Ther 1997; 8: 1935-43.
64. Xia D, Moyana T, Xiang J. Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors. Cell Res 2006; 16: 241-59.
65. Mazouz N, Ooms A, Moulin V, Van Meirvenne S, Uyttenhove C, Degiovanni G. CD40 triggering increases the efficiency of dendritic cells for antitumoral immunization. Cancer Immunol 2002; 2: 2.
66. Ribas A, Butterfield LH, Amarnani SN, Dissette VB, Kim D, Meng WS, Miranda GA, Wang HJ, McBride WH, Glaspy JA, Economou JS. CD40 cross-linking bypasses the absolute requirement for CD4 T-cells during immunization with melanoma antigen gene-modified dendritic cells. Ibid 2001; 61: 8787-93.
67. Diehl L, den Boer AT, Schoenberger SP, van der Voort EI, Schumacher TN, Melief CJ, Offringa R, Toes RE. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat Med 1999; 5: 774-9.
68. Tong AW, Stone MJ. Prospects for CD40-directed experimental therapy of human cancer. Cancer Gene Ther 2003; 10: 1-13.
69. Lapointe R, Bellemare-Pelletier A, Housseau F, Thibodeau J, Hwu P. CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T-cells. Cancer Res 2003; 63: 2836-43.
70. Mackey MF, Gunn JR, Ting PP, Kikutani H, Dranoff G, Noelle RJ, Barth RJ Jr. Protective immunity induced by tumor vaccines requires interaction between CD40 and its ligand, CD154. Cancer Res 1997; 57: 2569-74.
71. Yano Y, Ueda Y, Itoh T, Fuji N, Okugawa K, Naito K, Imura K, Kohara J, Hayashi T, Nakane K, Matsuura Y, Kawai K, Yamagishi H. A new strategy using autologous dendritic cells and lymphokine-activated killer cells for cancer immunotherapy: efficient maturation of DCs by co-culture with LAK cells in vitro. Oncol Rep 2006; 16: 147-52.
72. Murphy WJ, Welniak L, Back T, Hixon J, Subleski J, Seki N, Wigginton JM, Wilson SE, Blazar BR, Malyguine AM, Sayers TJ, Wiltrout RH. Synergistic anti-tumor responses after administration of agonistic antibodies to CD40 and IL-2: coordination of dendritic and CD8+ cell responses. J Immunol 2003; 170: 2727-33.
73. Welniak LA, Shorts L, Subleski J, Blazar BR, Wiltrout RH, Murphy WJ. Tumor regression by anti-CD-40 and interleukin-2: role of CD40 in hematopoietic cells and organ-specific effects. Biol Blood Marrow Transplant 2004; 10: 534-9.
74. Berner V, Liu H, Zhou Q, Alderson KL, Sun K, Weiss IM, Back TC, Longo DL, Blazar BR, Wiltrout RH, Welniak LA, Redelman D, Murphy WJ. IFN-gamma mediates CD4(+) T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy. Nat Med 2007; 13: 354-60.
75. Honeychurch J, Glennie MJ, Johnson PW, Illidge TM. Anti-CD40 monoclonal antibody therapy in combination with irradiation results in a CD8 T-cell-dependent immunity to B-cell lymphoma. Blood 2003; 102: 1449-57.
76. Luczynski W, Stasiak-Barmuta A, Ilendo E, Krawczuk-Rybak M, Malinowska I, Mitura-Lesiuk M, Parfienczyk A, Szymanski M. CD40 stimulation induces differentiation of acute lymphoblastic leukemia cells into dendritic cells. Acta Biochim Pol 2006; 53: 377-82.
77. D'Amico G, Marin V, Biondi A, Bonamino MH. Potential use of CD40 ligand for immunotherapy of childhood B-cell precursor acute lymphoblastic leukaemia. Best Pract Res Clin Haematol 2004; 17: 465-77.
78. Hock BD, McKenzie JL, Patton NW, Drayson M, Taylor K, Wakeman C, Kantarjian H, Giles F, Albitar M. Circulating levels and clinical significance of soluble CD40 in patients with hematologic malignancies. Cancer 2006; 106: 2148-57.
79. Vonderheide RH, Dutcher JP, Anderson JE, Eckhardt SG, Stephans KF, Razvillas B, Garl S, Butine MD, Perry VP, Armitage RJ, Ghalie R, Caron DA, Gribben JG. Phase I study of recombinant human CD40 ligand in cancer patients. J Clin Oncol 2001; 19: 3280-7.